Dosage/Direction for Use
Adult: As 0.05% susp: 100 mcg into each nostril once daily, increased to 200 mcg into each nostril daily if needed.
Child: 3-11 yr 50 mcg into each nostril once daily; ≥12 yr Same as adult dose.
Adult: 100 mcg into each nostril once daily, increased to bid after 5-6 wk if needed.
Adult: As dry powd inhaler: Mild to moderate: Initially, 400 mcg once daily in the evening. Maintenance dose: 200 mcg 1-2 times daily. Severe: Initially, 400 mcg bid, titrated to the lowest effective dose once symptoms are controlled.
Child: ≥12 yr Same as adult dose.
Adult: As 0.1% cream/oint: Apply a thin film to affected area once daily. As 0.1% lotion: Apply a few drops to affected area once daily, massage lightly until it disappears.
Child: ≥2 yr As 0.1% cream/oint: Apply a thin film to affected area once daily for not more than 3 wk. ≥12 yr As 0.1% lotion: Same as adult dose.
Patient w/ heart failure, DM, GI disorders, myasthenia gravis, acute MI, cataracts/glaucoma, thyroid disease; history of seizure disorders; untreated localised infection of the nasal mucosa (e.g. herpes simplex), recent nasal surgery/trauma; patient w/ or at risk of osteoporosis. Patient w/ facial rosacea, acne vulgaris, skin atrophy, perioral dermatitis, perianal/genital pruritis, napkin eruptions; bacterial, viral, parasitical and fungal infections; varicella, syphilis or post-vaccine reactions. Avoid abrupt withdrawal when switching from systemic to oral or orally inhaled corticosteroid. Hepatic and renal impairment. Pregnancy and lactation. Monitoring Parameters Monitor pulmonary function, signs/symptoms of candidiasis, ocular effects.
Hypothalmic-pituitary-adrenal (HPA) axis suppression, immunosuppression, Kaposi sarcoma, oral candidiasis, psychiatric disturbances, headache, allergic rhinitis, pharyngitis, upper resp tract infection, sinusitis, dysmenorrhoea, musculoskeletal pain, back pain, dyspepsia, myalgia, abdominal pain, nausea.
Potentially Fatal: Paradoxical bronchospasm, anaphylaxis.
Symptoms: Suppression of hypothalamic-pituitary-adrenal (HPA) function resulting in secondary adrenal insufficiency. Management: Gradually reduce dose.
Strong CYP3A4 inhibitors (e.g. ketoconazole) may increase systemic exposure of mometasone.
Mometasone depresses the formation, release and activity of endogenous inflammatory chemical mediators (e.g. kinins, histamine, liposomal enzymes and prostaglandin). It inhibits the margination and subsequent cell migration to the injury site, reverses vascular dilatation and permeability, resulting in decreased access of cells to the area of injury.
Onset: Inhalation: ≥1-2 wk.
Absorption: Poorly absorbed (<1%) after inhalation, intranasal use and topical application. Time to peak plasma concentration: 0.5-2.5 hr (inhalation).
Distribution: Volume of distribution: 152 L. Plasma protein binding: 98-99%.
Metabolism: Undergoes hepatic metabolism by CYP3A4 isoenzyme.
Excretion: Via faeces and urine (lesser extent). Terminal elimination half-life: Approx 5 hr.
Inhalation: Store between 20-25°C. Protect from heat or open flame. Nasal: Store at 25°C. Protect from light. Topical/Cutaneous: Store between 2-30°C.
D07AC13 - mometasone ; Belongs to the class of potent (group III) corticosteroids. Used in the treatment of dermatological diseases.
D07XC03 - mometasone ; Belongs to the class of potent (group III) corticosteroids in other combinations. Used in the treatment of dermatological diseases.
R03BA07 - mometasone ; Belongs to the class of other inhalants used in the treatment of obstructive airway diseases, glucocorticoids.
R01AD09 - mometasone ; Belongs to the class of topical corticosteroids used for prophylaxis and treatment of allergic rhinitis.